Acrux describes what has been dubbed the ‘spay-on pill’, as a fourth-generation progestin contraceptive that has no androgenic hormonal effects, and a good safety profile. It says it will develop the contraceptive spray which contains the contraceptive drug, Netsorone, and then seek marketing partners as it works towards commercialization of the product.
Acrux CEO, Igor Gonda, said, “The target features of Nestorone MDTS are: a convenient daily spray onto the arm that is more discreet and less irritating to the skin than a patch, and we believe, will prove to have a better safety profile than other hormonal contraceptives. Market research has shown that many women will prefer the ease and convenience of this method to swallowing pills, taking injections, or wearing patches,”
Gonda also noted that Acrux sees great market potential for Nestorone MDTS given the fact that annual worldwide sales of hormonal contraceptives exceed $4 billion, and sales of transdermal contraceptive patches in the US alone are more than US$400 million a year.